Abstract: A stable composition comprising of genetically engineered vesiculovirus expressing a heterologous protein are disclosed. Said composition comprises pharmaceutically acceptable excipients selected from buffer, salt, and a globular protein individually and combination thereof. The said compositions are designed to be stored at widely available storage conditions for enhancing the stability profile. The stability profiles achieved by the present disclosure renders the said composition to be deployed globally at affordable costs.
0
| # | Name | Date |
|---|---|---|
| 1 | 202341059628-STATEMENT OF UNDERTAKING (FORM 3) [05-09-2023(online)].pdf | 2023-09-05 |
| 2 | 202341059628-PROVISIONAL SPECIFICATION [05-09-2023(online)].pdf | 2023-09-05 |
| 3 | 202341059628-POWER OF AUTHORITY [05-09-2023(online)].pdf | 2023-09-05 |
| 4 | 202341059628-FORM 1 [05-09-2023(online)].pdf | 2023-09-05 |
| 5 | 202341059628-FIGURE OF ABSTRACT [05-09-2023(online)].pdf | 2023-09-05 |
| 6 | 202341059628-DRAWINGS [05-09-2023(online)].pdf | 2023-09-05 |
| 7 | 202341059628-DRAWING [20-08-2024(online)].pdf | 2024-08-20 |
| 8 | 202341059628-COMPLETE SPECIFICATION [20-08-2024(online)].pdf | 2024-08-20 |
| 9 | 202341059628-Covering Letter [31-08-2024(online)].pdf | 2024-08-31 |
| 10 | 202341059628-CORRESPONDENCE-OTHERS [04-09-2024(online)].pdf | 2024-09-04 |
| 11 | 202341059628-FORM-5 [05-09-2024(online)].pdf | 2024-09-05 |